Moleculin Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MBRX and other ETFs, options, and stocks.

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. 

CEO
Walter V. Klemp
CEOWalter V. Klemp
Employees
17
Employees17
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
2015
Founded2015
Employees
17
Employees17

MBRX Key Statistics

Market cap
10.23M
Market cap10.23M
Price-Earnings ratio
-0.03
Price-Earnings ratio-0.03
Dividend yield
Dividend yield
Average volume
1.51M
Average volume1.51M
High today
$0.6257
High today$0.6257
Low today
$0.5022
Low today$0.5022
Open price
$0.58
Open price$0.58
Volume
1.82M
Volume1.82M
52 Week high
$15.75
52 Week high$15.75
52 Week low
$0.1614
52 Week low$0.1614

Stock Snapshot

Moleculin Biotech(MBRX) stock is priced at $0.50, giving the company a market capitalization of 10.23M. It carries a P/E multiple of -0.03.

As of 2026-09-23, Moleculin Biotech(MBRX) stock has fluctuated between $0.50 and $0.63. The current price stands at $0.50, placing the stock +0.0% above today's low and -19.7% off the high.

Moleculin Biotech(MBRX) shares are trading with a volume of 1.82M, against a daily average of 1.51M.

In the last year, Moleculin Biotech(MBRX) shares hit a 52-week high of $15.75 and a 52-week low of $0.16.

In the last year, Moleculin Biotech(MBRX) shares hit a 52-week high of $15.75 and a 52-week low of $0.16.

MBRX News

TipRanks 12h
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio - TipRanks

...

Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio - TipRanks
TipRanks 13h
Moleculin Biotech secures Mexican patent protecting Annamycin through 2040

Moleculin Biotech (MBRX) announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company’s global intellectual propert...

TipRanks 5d
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice

The latest announcement is out from Moleculin Biotech ( (MBRX) ). On September 15, 2026, Moleculin Biotech disclosed that it had received a Nasdaq Staff Determ...

People also own

Based on the portfolios of people who own MBRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.